ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
PSMA-PET imaging product Illuccix officially launches in Canada for prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 253005" data-attributes="member: 13851"><p><strong>Illuccix is approved by Health Canada for imaging in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on an elevated PSA level.</strong></p><p></p><p>[URL unfurl="true"]https://www.urologytimes.com/view/psma-pet-imaging-product-illuccix-officially-launches-in-canada[/URL]</p><p></p><p></p><p><em><strong>The first patients in a commercial setting in Canada have been imaged with Illuccix, a kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection, a radioactive diagnostic agent indicated for PET imaging of PSMA-positive lesions in patients with prostate cancer.1,2</strong></em></p><p><em></em></p><p><em>The commercial launch follows the approval of Illuccix by Health Canada in October 2022. <strong>The agency approved Illuccix for imaging in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on an elevated PSA level.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>"The launch of Illuccix in Canada marks an important milestone for Telix and the approximately 24,000 men who will be diagnosed with prostate cancer in the country this year. The widespread availability of PSMA-PET imaging, via Telix's distribution partner Isologic, will help deliver on a significant unmet medical need for the men in Canada and their families affected by this disease,” </strong>Kevin Richardson, chief executive officer for Telix Americas, stated in a press release.</em></p><h3></h3><h3></h3><h3></h3><h3><strong>Clinical support for Ga PSMA-11</strong></h3><p><em><strong>Evidence of the efficacy of Ga PSMA-11 has been demonstrated in clinical trials, including 2 prospective trials with a total of 960 men with prostate cancer who each received 1 injection of the agent.3</strong></em></p><p><em></em></p><p><em>In the first trial, 325 patients who were candidates for surgical removal of the prostate gland and pelvic lymph nodes and were considered at higher risk for metastasis underwent PET/CT or PET/MRI scans performed with Ga PSMA-11.<strong> Of the patients who went on to undergo surgery, Ga PSMA-11 demonstrated a clinically important rate of metastatic cancer confirmed by surgical pathology in patients with positive readings in the pelvic lymph nodes.</strong></em></p><p><em></em></p><p><em>In the second trial, of 635 patients who had rising serum PSA levels after initial prostate surgery or radiotherapy, 74% had at least 1 positive lesion detected by Ga PSMA-11 in at least 1 body region. <strong>In total, 91% of patients with positive Ga PSMA-11 readings who had correlative tissue pathology from biopsies, who also had results from baseline or follow-up imaging by conventional methods, and serial PSA levels available for comparison, also had local recurrence or metastasis of prostate cancer confirmed.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 253005, member: 13851"] [B]Illuccix is approved by Health Canada for imaging in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on an elevated PSA level.[/B] [URL unfurl="true"]https://www.urologytimes.com/view/psma-pet-imaging-product-illuccix-officially-launches-in-canada[/URL] [I][B]The first patients in a commercial setting in Canada have been imaged with Illuccix, a kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection, a radioactive diagnostic agent indicated for PET imaging of PSMA-positive lesions in patients with prostate cancer.1,2[/B] The commercial launch follows the approval of Illuccix by Health Canada in October 2022. [B]The agency approved Illuccix for imaging in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on an elevated PSA level. "The launch of Illuccix in Canada marks an important milestone for Telix and the approximately 24,000 men who will be diagnosed with prostate cancer in the country this year. The widespread availability of PSMA-PET imaging, via Telix's distribution partner Isologic, will help deliver on a significant unmet medical need for the men in Canada and their families affected by this disease,” [/B]Kevin Richardson, chief executive officer for Telix Americas, stated in a press release.[/I] [HEADING=2][/HEADING] [HEADING=2][/HEADING] [HEADING=2][/HEADING] [HEADING=2][B]Clinical support for Ga PSMA-11[/B][/HEADING] [I][B]Evidence of the efficacy of Ga PSMA-11 has been demonstrated in clinical trials, including 2 prospective trials with a total of 960 men with prostate cancer who each received 1 injection of the agent.3[/B] In the first trial, 325 patients who were candidates for surgical removal of the prostate gland and pelvic lymph nodes and were considered at higher risk for metastasis underwent PET/CT or PET/MRI scans performed with Ga PSMA-11.[B] Of the patients who went on to undergo surgery, Ga PSMA-11 demonstrated a clinically important rate of metastatic cancer confirmed by surgical pathology in patients with positive readings in the pelvic lymph nodes.[/B] In the second trial, of 635 patients who had rising serum PSA levels after initial prostate surgery or radiotherapy, 74% had at least 1 positive lesion detected by Ga PSMA-11 in at least 1 body region. [B]In total, 91% of patients with positive Ga PSMA-11 readings who had correlative tissue pathology from biopsies, who also had results from baseline or follow-up imaging by conventional methods, and serial PSA levels available for comparison, also had local recurrence or metastasis of prostate cancer confirmed.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
PSMA-PET imaging product Illuccix officially launches in Canada for prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top